The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022

被引：49
|
作者：
Pang, Xiaojing [1 ]
Liu, Yang [1 ]
Li, Hua [1 ,2 ]
Chen, Lixia [1 ]
机构：
[1] Shenyang Pharmaceut Univ, Wuya Coll Innovat, Key Lab Struct Based Drug Design & Discovery, Minist Educ, Shenyang 110016, Peoples R China
[2] Fujian Univ Tradit Chinese Med, Inst Struct Pharmacol & TCM Chem Biol, Coll Pharm, Fuzhou 350122, Peoples R China
来源：
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2023年 / 257卷
基金：
中国国家自然科学基金;
关键词：
COVID-19; SARS-CoV-2; M pro inhibitors; Drug repurposing; Drug design; COVALENT INHIBITORS; GENOME SEQUENCE; ACHILLES-HEEL; CORONAVIRUS; DISCOVERY; EBSELEN; IDENTIFICATION; REPLICATION; DESIGN; 3C;
D O I：
10.1016/j.ejmech.2023.115491
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. The main protease (Mpro) of SARS-CoV-2 plays a central role in viral replication and transcription and represents an attractive drug target for fighting COVID-19. Many SARS-CoV-2 Mpro inhibitors have been reported, including covalent and noncovalent inhibitors. The SARS-CoV-2 Mpro inhibitor PF-07321332 (Nirmatrelvir) designed by Pfizer has been put on the market. This paper briefly introduces the structural characteristics of SARS-CoV-2 Mpro and summarizes the research progress of SARS-CoV-2 Mpro inhibitors from the aspects of drug repurposing and drug design. These information will provide a basis for the drug development of treating the infection of SARS-CoV-2 and even other coronaviruses in the future.
引用
收藏
页数：20
相关论文
共 50 条
  • [41] Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2
    Ghahremanpour, Mohammad M.
    Tirado-Rives, Julian
    Deshmukh, Maya
    Ippolito, Joseph A.
    Zhang, Chun-Hui
    de Vaca, Israel Cabeza
    Liosi, Maria-Elena
    Anderson, Karen S.
    Jorgensen, William L.
    ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (12): : 2526 - 2533
  • [42] Dinitrosyl iron complexes (DNICs) as inhibitors of the SARS-CoV-2 main protease
    Pectol, D. Chase
    DeLaney, Christopher R.
    Zhu, Jiyun
    Mellott, Drake M.
    Katzfuss, Ardala
    Taylor, Zane W.
    Meek, Thomas D.
    Darensbourg, Marcetta Y.
    CHEMICAL COMMUNICATIONS, 2021, 57 (67) : 8352 - 8355
  • [43] Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease
    Mengist, Hylemariam Mihiretie
    Dilnessa, Tebelay
    Jin, Tengchuan
    FRONTIERS IN CHEMISTRY, 2021, 9
  • [44] Review on development of potential inhibitors of SARS-CoV-2 main protease (MPro)
    Katre, Soumya Gulab
    Asnani, Alpana Jagdish
    Pratyush, Kumar
    Sakharkar, Nilima Gangadhar
    Bhope, Ashwini Gajanan
    Sawarkar, Kanchan Tekram
    Nimbekar, Vaibhav Santosh
    FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 8 (01)
  • [45] Inhibitors of SARS-CoV-2 main protease: Biological efficacy and toxicity aspects
    Viskupicova, Jana
    Rezbarikova, Petronela
    Kovacikova, Lucia
    Kandarova, Helena
    Majekova, Magdalena
    TOXICOLOGY IN VITRO, 2023, 92
  • [46] Potential Self-Peptide Inhibitors of the SARS-CoV-2 Main Protease
    Banerjee, Arkadeep
    Gosavi, Shachi
    PROTEIN SCIENCE, 2021, 30 : 46 - 47
  • [47] Computational study on peptidomimetic inhibitors against SARS-CoV-2 main protease
    Somboon, Tuanjai
    Mahalapbutr, Panupong
    Sanachai, Kamonpan
    Maitarad, Phornphimon
    Lee, Vannajan Sanghiran
    Hannongbua, Supot
    Rungrotmongkol, Thanyada
    JOURNAL OF MOLECULAR LIQUIDS, 2021, 322
  • [48] Exploring covalent inhibitors of SARS-CoV-2 main protease: from peptidomimetics to novel scaffolds
    Atatreh, Noor
    Mahgoub, Radwa E.
    Ghattas, Mohammad A.
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2025, 40 (01)
  • [49] Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives
    Citarella, Andrea
    Dimasi, Alessandro
    Moi, Davide
    Passarella, Daniele
    Scala, Angela
    Piperno, Anna
    Micale, Nicola
    BIOMOLECULES, 2023, 13 (09)
  • [50] In silico screening of potential SARS-COV-2 MAIN protease inhibitors from thymus Schimperi
    Mengist, H. M.
    Zunera, K.
    Fentahun, A.
    CLINICA CHIMICA ACTA, 2024, 558 : 28 - 28
12345